Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.43 |
| ▸ | IKZF3 | Q9UKT9 | 12/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 4/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25816414 | 0.90 | CRBN (0.48) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL31101716 | 0.79 | PBRM1 (0.47) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL25816369 | 0.78 | PBRM1 (0.56) | PBRM1SMARCA2SMARCA4 | |
| SCHEMBL24421474 | 0.77 | CRBN (0.39) | CRBNDDB1ESR1BTK | |
| SCHEMBL25816186 | 0.77 | CRBN (0.64) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL24421179 | 0.77 | CRBN (0.40) | CRBNIKZF3ESR1BTK | |
| SCHEMBL24421451 | 0.76 | CRBN (0.38) | CRBNESR1BTK | |
| SCHEMBL24420866 | 0.75 | CRBN (0.38) | CRBNDDB1ESR1BTK | |
| SCHEMBL24421568 | 0.75 | CRBN (0.37) | CRBNESR1BTK | |
| SCHEMBL31331243 | 0.75 | PBRM1 (0.47) | CRBNPBRM1SMARCA2SMARCA4BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129506-A1 | POTENT AND SELECTIVE SMARCA2 DEGRADING CHIMERIC MOLECULES AS CANCER THERAPEUTICS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-06 | — | — | WO | disclosed |